BioPharmSignal logoBioPharmSignal

Biotech News

Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

Adial Pharmaceuticals (ADIL)Adial PharmaceuticalsCommercial

AD04 Program Aligned with NIAAA's New Inclusion of Non-Abstinence Solutions, Validating Commercial and Government Market Potential

GLEN ALLEN, Va., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical...

Related news

ADILAdial Pharmaceuticals2024-01-18 08:30 EST

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

ADILAdial Pharmaceuticals2023-08-28 08:30 EST

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism

View all latest news

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biotechnology company focused on treatments for alcohol use disorder and related addiction biology. Its story is centered on the difficult intersection of behavioral health, relapse prevention, and chronic disease management.

Recent company news

ADILAdial Pharmaceuticals2025-06-11 08:00 EST

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

ADILAdial Pharmaceuticals2025-05-15 08:30 EST

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ADILAdial Pharmaceuticals2025-05-13 08:30 EST

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

ADILAdial Pharmaceuticals2025-05-08 08:30 EST

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

ADILAdial Pharmaceuticals2025-05-02 11:48 EST

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

Stock data

Close
6.22 USD
Market cap
5.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States